Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients With Fibrostenosing Crohn's Disease

NCT07683325 is registered in ClinicalTrials.gov with Agomab Spain S.L.U. as lead sponsor.

NCT NCT07683325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07683325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients With Fibrostenosing Crohn's Disease
Lead sponsor
Agomab Spain S.L.U.
Phase
Phase 2
Overall status
Recruiting
Start date
October 30, 2026
Completion date
June 30, 2029
Enrollment
320 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

fibrostenotic crohn's disease